Cargando…

Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients

Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone re...

Descripción completa

Detalles Bibliográficos
Autores principales: Baron, Max, Drohat, Philip, Crawford, Brooke, Hornicek, Francis J., Best, Thomas M., Kouroupis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604230/
https://www.ncbi.nlm.nih.gov/pubmed/37892917
http://dx.doi.org/10.3390/bioengineering10101187
_version_ 1785126786853502976
author Baron, Max
Drohat, Philip
Crawford, Brooke
Hornicek, Francis J.
Best, Thomas M.
Kouroupis, Dimitrios
author_facet Baron, Max
Drohat, Philip
Crawford, Brooke
Hornicek, Francis J.
Best, Thomas M.
Kouroupis, Dimitrios
author_sort Baron, Max
collection PubMed
description Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor. The amount of bone removed in an OS patient leaves too large of a deficit for bone to form on its own and requires reconstruction with metal implants or allografts. Both methods require the bone to heal, either to the implant or across the allograft junction, often in the setting of marrow-killing chemotherapy. Therefore, the issue of bone regeneration within the surgically resected margins remains an important challenge for the patient, family, and treating providers. Mesenchymal stem/stromal cells (MSCs) are potential agents for enhancing bone regeneration post tumor resection. MSCs, used with scaffolds and growth factors, show promise in fostering bone regeneration in OS cases. We spotlight two MSC types—bone marrow-derived (BM-MSCs) and adipose tissue-derived (ASCs)—highlighting their bone regrowth facilitation and immunomodulatory effects on immune cells like macrophages and T cells, enhancing therapeutic outcomes. The objective of this review is two-fold: review work demonstrating any ability of MSCs to target the deranged immune system in the OS microenvironment, and synthesize the available literature on the use of MSCs as a therapeutic option for stimulating bone regrowth in OS patients post bone resection. When it comes to repairing bone defects, both MB-MSCs and ASCs hold great potential for stimulating bone regeneration. Research has showcased their effectiveness in reconstructing bone defects while maintaining a non-tumorigenic role following wide resection of bone tumors, underscoring their capability to enhance bone healing and regeneration following tumor excisions.
format Online
Article
Text
id pubmed-10604230
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106042302023-10-28 Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients Baron, Max Drohat, Philip Crawford, Brooke Hornicek, Francis J. Best, Thomas M. Kouroupis, Dimitrios Bioengineering (Basel) Review Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor. The amount of bone removed in an OS patient leaves too large of a deficit for bone to form on its own and requires reconstruction with metal implants or allografts. Both methods require the bone to heal, either to the implant or across the allograft junction, often in the setting of marrow-killing chemotherapy. Therefore, the issue of bone regeneration within the surgically resected margins remains an important challenge for the patient, family, and treating providers. Mesenchymal stem/stromal cells (MSCs) are potential agents for enhancing bone regeneration post tumor resection. MSCs, used with scaffolds and growth factors, show promise in fostering bone regeneration in OS cases. We spotlight two MSC types—bone marrow-derived (BM-MSCs) and adipose tissue-derived (ASCs)—highlighting their bone regrowth facilitation and immunomodulatory effects on immune cells like macrophages and T cells, enhancing therapeutic outcomes. The objective of this review is two-fold: review work demonstrating any ability of MSCs to target the deranged immune system in the OS microenvironment, and synthesize the available literature on the use of MSCs as a therapeutic option for stimulating bone regrowth in OS patients post bone resection. When it comes to repairing bone defects, both MB-MSCs and ASCs hold great potential for stimulating bone regeneration. Research has showcased their effectiveness in reconstructing bone defects while maintaining a non-tumorigenic role following wide resection of bone tumors, underscoring their capability to enhance bone healing and regeneration following tumor excisions. MDPI 2023-10-13 /pmc/articles/PMC10604230/ /pubmed/37892917 http://dx.doi.org/10.3390/bioengineering10101187 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Baron, Max
Drohat, Philip
Crawford, Brooke
Hornicek, Francis J.
Best, Thomas M.
Kouroupis, Dimitrios
Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title_full Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title_fullStr Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title_full_unstemmed Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title_short Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
title_sort mesenchymal stem/stromal cells: immunomodulatory and bone regeneration potential after tumor excision in osteosarcoma patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604230/
https://www.ncbi.nlm.nih.gov/pubmed/37892917
http://dx.doi.org/10.3390/bioengineering10101187
work_keys_str_mv AT baronmax mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients
AT drohatphilip mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients
AT crawfordbrooke mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients
AT hornicekfrancisj mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients
AT bestthomasm mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients
AT kouroupisdimitrios mesenchymalstemstromalcellsimmunomodulatoryandboneregenerationpotentialaftertumorexcisioninosteosarcomapatients